Rep. Julie Johnson Sells Off Shares of Bristol Myers Squibb Company (NYSE:BMY)

Representative Julie Johnson (D-Texas) recently sold shares of Bristol Myers Squibb Company (NYSE:BMY). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bristol Myers Squibb stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Bristol Myers Squibb Trading Down 2.3%

Shares of Bristol Myers Squibb stock opened at $55.30 on Friday. The firm’s 50 day simple moving average is $51.91 and its two-hundred day simple moving average is $48.13. The firm has a market capitalization of $112.58 billion, a price-to-earnings ratio of 18.68, a PEG ratio of 9.15 and a beta of 0.29. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a current ratio of 1.27, a quick ratio of 1.17 and a debt-to-equity ratio of 2.39.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $1.63 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The firm had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.80 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. Analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.6%. The ex-dividend date is Friday, January 2nd. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 85.14%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. HSBC reiterated a “hold” rating and issued a $53.00 target price on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Scotiabank reissued a “sector perform” rating and set a $60.00 target price (up previously from $53.00) on shares of Bristol Myers Squibb in a report on Friday, January 9th. Morgan Stanley restated an “underweight” rating and set a $37.00 target price (up from $36.00) on shares of Bristol Myers Squibb in a research report on Friday, December 12th. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, November 17th. Seven investment analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and an average target price of $56.86.

Institutional Investors Weigh In On Bristol Myers Squibb

A number of institutional investors have recently modified their holdings of the business. Perigon Wealth Management LLC increased its stake in Bristol Myers Squibb by 22.8% during the 4th quarter. Perigon Wealth Management LLC now owns 72,670 shares of the biopharmaceutical company’s stock worth $3,920,000 after buying an additional 13,485 shares in the last quarter. Pacific Sage Partners LLC acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter worth approximately $207,000. BridgePort Financial Solutions LLC raised its stake in Bristol Myers Squibb by 228.4% in the 4th quarter. BridgePort Financial Solutions LLC now owns 16,021 shares of the biopharmaceutical company’s stock valued at $864,000 after purchasing an additional 11,143 shares during the last quarter. Tempus Wealth Planning LLC boosted its stake in Bristol Myers Squibb by 2.0% during the 4th quarter. Tempus Wealth Planning LLC now owns 14,517 shares of the biopharmaceutical company’s stock worth $783,000 after purchasing an additional 282 shares during the last quarter. Finally, Armstrong Fleming & Moore Inc raised its position in shares of Bristol Myers Squibb by 12.2% in the fourth quarter. Armstrong Fleming & Moore Inc now owns 9,015 shares of the biopharmaceutical company’s stock valued at $486,000 after buying an additional 983 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.